Skip to main content
Erschienen in: Neurological Sciences 10/2020

29.04.2020 | Original Article

Experience with rituximab therapy in a real-life sample of multiple sclerosis patients

verfasst von: Angelo Bellinvia, Elio Prestipino, Emilio Portaccio, Lorenzo Razzolini, Mattia Fonderico, Roberto Fratangelo, Laura Tudisco, Luisa Pastò, Maria P. Amato

Erschienen in: Neurological Sciences | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Multiple sclerosis (MS) is an autoimmune, neuroinflammatory, and neurodegenerative disease of the central nervous system. B cells have recently emerged as a promising target to significantly reduce inflammatory disease activity in MS, with successful trial studies using antiCD20 therapies. However, real-life data about safety and efficacy are limited.

Objectives

To analyze the clinical and radiological inflammatory activity, adherence to therapy, and safety of rituximab (RTX) in an MS patients’ sample, treated from 2015 to 2018 in our center

Patients and methods

Retrospective study on prospectively collected data about relapses, disability progression, and radiological activity (new T2 lesions and Gd-enhancing lesions) were recorded and used to assess no evidence of disease activity (NEDA) at 12 months. RTX-related adverse events were recorded. RTX was administered intravenously at a dosage of 1000 mg twice 2 weeks apart, then every 6 months.

Results

Sixty-nine patients were included. Fifty-three (76.8%) had a relapsing-remitting, two a primary progressive course, and 14 a secondary progressive course. The mean follow-up period was 16 ± 9.7 months. Thirty-five (50.7%) patients had relapses in the year prior to RTX therapy, with a mean annualized relapse rate of 0.75, significantly reduced to 0.36 at 12 months (p < 0.001). Among the 36 patients included in the study who had an MRI available at 12 months, MRI activity was reduced from 88% (n = 32) to 8.3% (n = 3) at follow-up (p < 0.001). Twelve (17.4%) patients suspended RTX during the study.

Conclusions

Our real-life experience confirms that off-label therapy with RTX may represent a valid, cost-effective therapeutic option in MS.
Literatur
10.
Zurück zum Zitat Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302. https://doi.org/10.1002/ana.22366CrossRefPubMedPubMedCentral Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302. https://​doi.​org/​10.​1002/​ana.​22366CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F (2018) ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 24:96–120. https://doi.org/10.1177/1352458517751049CrossRefPubMed Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F (2018) ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 24:96–120. https://​doi.​org/​10.​1177/​1352458517751049​CrossRefPubMed
13.
Zurück zum Zitat Kappos L, Butzkueven H, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S, Trojano M, On Behalf of the Tysabri® Observational Program (TOP) Investigators (2018) Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Mult Scler J 24:963–973. https://doi.org/10.1177/1352458517709619CrossRef Kappos L, Butzkueven H, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S, Trojano M, On Behalf of the Tysabri® Observational Program (TOP) Investigators (2018) Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Mult Scler J 24:963–973. https://​doi.​org/​10.​1177/​1352458517709619​CrossRef
14.
Zurück zum Zitat NIH/NCI (2017) Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP. In: Protocol NIH/NCI (2017) Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP. In: Protocol
16.
Zurück zum Zitat Cree B, Lamb S, Chin A, Bonovich D, Islar J, Waubant E, Genain C (2004) Tolerability and effects of rituximab (anti-CD20 antibody) in neuromyelitis optica (NMO) and rapidly worsening multiple sclerosis (MS). Neurology 62:06.90 Cree B, Lamb S, Chin A, Bonovich D, Islar J, Waubant E, Genain C (2004) Tolerability and effects of rituximab (anti-CD20 antibody) in neuromyelitis optica (NMO) and rapidly worsening multiple sclerosis (MS). Neurology 62:06.90
17.
Zurück zum Zitat Salzer J, Svenningsson R, Alping P, Novakova L, Björck A, Fink K, Islam-Jakobsson P, Malmeström C, Axelsson M, Vågberg M, Sundström P, Lycke J, Piehl F, Svenningsson A (2016) Rituximab in multiple sclerosis a retrospective observational study on safety and efficacy. Neurology 87:2074–2081CrossRef Salzer J, Svenningsson R, Alping P, Novakova L, Björck A, Fink K, Islam-Jakobsson P, Malmeström C, Axelsson M, Vågberg M, Sundström P, Lycke J, Piehl F, Svenningsson A (2016) Rituximab in multiple sclerosis a retrospective observational study on safety and efficacy. Neurology 87:2074–2081CrossRef
25.
Zurück zum Zitat Alping P, Askling J, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T (2020) Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Ann Neurol 87:688–699. https://doi.org/10.1002/ana.25701CrossRefPubMed Alping P, Askling J, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T (2020) Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Ann Neurol 87:688–699. https://​doi.​org/​10.​1002/​ana.​25701CrossRefPubMed
27.
Zurück zum Zitat Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L, OPERA I and OPERA II Clinical Investigators (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376:221–234. https://doi.org/10.1056/NEJMoa1601277CrossRefPubMed Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L, OPERA I and OPERA II Clinical Investigators (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376:221–234. https://​doi.​org/​10.​1056/​NEJMoa1601277CrossRefPubMed
28.
Zurück zum Zitat Paul F, Cartron G (2019) Infusion-related reactions to rituximab: frequency, mechanisms and predictors. Expert Rev Clin Immunol 15:383–389CrossRef Paul F, Cartron G (2019) Infusion-related reactions to rituximab: frequency, mechanisms and predictors. Expert Rev Clin Immunol 15:383–389CrossRef
Metadaten
Titel
Experience with rituximab therapy in a real-life sample of multiple sclerosis patients
verfasst von
Angelo Bellinvia
Elio Prestipino
Emilio Portaccio
Lorenzo Razzolini
Mattia Fonderico
Roberto Fratangelo
Laura Tudisco
Luisa Pastò
Maria P. Amato
Publikationsdatum
29.04.2020
Verlag
Springer International Publishing
Erschienen in
Neurological Sciences / Ausgabe 10/2020
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-020-04434-1

Weitere Artikel der Ausgabe 10/2020

Neurological Sciences 10/2020 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.